Clover Health Investments vs Quest Diagnostics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Clover Health Investments Corp (CLOV)

Q3 202618 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

July 202618 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

Latest18 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

Quest Diagnostics Incorporated (DGX)

Q3 202624 Jun – 5 Aug 2026

▲4

Quest raises 2026 outlook on strong Q2 and new test approval

New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.
This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.
Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.
A new partnership that adds incremental testing volume and shows Quest winning new business.
Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.
The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.
Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.
Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.

July 202624 Jun – 5 Aug 2026

▲4

Quest raises 2026 outlook on strong Q2 and new test approval

New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.
This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.
Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.
A new partnership that adds incremental testing volume and shows Quest winning new business.
Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.
The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.
Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.
Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.

Latest24 Jun – 5 Aug 2026

▲4

Quest raises 2026 outlook on strong Q2 and new test approval

New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.
This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.
Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.
A new partnership that adds incremental testing volume and shows Quest winning new business.
Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.
The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.
Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.
Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.